Zealand Pharma A/S Beat Consensus Estimates

Zealand Pharma A/S (ZLDPF) reported earnings of $8.61 per share on revenue of $698.62 million for the second quarter ended June 2026. The consensus estimate was a loss of $0.42 per share. The company beat consensus estimates by 2,150.00% while revenue fell 49.45% compared to the same quarter a year ago.

Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. The company's pipeline includes ZP4207, single-dose rescue treatment for acute, severe hypoglycemia; ZP1848 for short bowel syndrome and ZP4207, multiple-dose version intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management and other earlier-stage clinical and preclinical peptide therapeutics are in clinical stage. Zealand Pharma A/S is based in Copenhagen, Denmark.